Lipocalin-2 and calprotectin as stool biomarkers for predicting necrotizing enterocolitis in premature neonates.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
10
03
2021
accepted:
19
07
2021
revised:
15
06
2021
pubmed:
2
9
2021
medline:
29
3
2022
entrez:
1
9
2021
Statut:
ppublish
Résumé
Necrotizing enterocolitis (NEC) is a major challenge for premature infants in neonatal intensive care units and efforts toward the search for indicators that could be used to predict the development of the disease have given limited results until now. In this study, stools from 132 very low birth weight infants were collected daily in the context of a multi-center prospective study aimed at investigating the potential of fecal biomarkers for NEC prediction. Eight infants (~6%) received a stage 3 NEC diagnosis. Their stools collected up to 10 days before diagnosis were included and matched with 14 non-NEC controls and tested by ELISA for the quantitation of eight biomarkers. Biomarkers were evaluated in all available stool samples leading to the identification of lipocalin-2 and calprotectin as the two most reliable predicting markers over the 10-day period prior to NEC development. Pooling the data for each infant confirmed the significance of lipocalin-2 and calprotectin, individually and in combination 1 week in advance of the NEC clinical diagnosis. The lipocalin-2 and calprotectin tandem represents a significant biomarker signature for predicting NEC development. Although not yet fulfilling the "perfect biomarker" criteria, it represents a first step toward it. Stool biomarkers can be used to predict NEC development in very low birth weight infants more than a week before the diagnosis. LCN2 was identified as a new robust biomarker for predicting NEC development, which used in conjunction with CALPRO, allows the identification of more than half of the cases that will develop NEC in very low birth weight infants. Combining more stool markers with the LCN2/CALPRO tandem such as PGE2 can further improve the algorithm for the prediction of NEC development.
Sections du résumé
BACKGROUND
Necrotizing enterocolitis (NEC) is a major challenge for premature infants in neonatal intensive care units and efforts toward the search for indicators that could be used to predict the development of the disease have given limited results until now.
METHODS
In this study, stools from 132 very low birth weight infants were collected daily in the context of a multi-center prospective study aimed at investigating the potential of fecal biomarkers for NEC prediction. Eight infants (~6%) received a stage 3 NEC diagnosis. Their stools collected up to 10 days before diagnosis were included and matched with 14 non-NEC controls and tested by ELISA for the quantitation of eight biomarkers.
RESULTS
Biomarkers were evaluated in all available stool samples leading to the identification of lipocalin-2 and calprotectin as the two most reliable predicting markers over the 10-day period prior to NEC development. Pooling the data for each infant confirmed the significance of lipocalin-2 and calprotectin, individually and in combination 1 week in advance of the NEC clinical diagnosis.
CONCLUSIONS
The lipocalin-2 and calprotectin tandem represents a significant biomarker signature for predicting NEC development. Although not yet fulfilling the "perfect biomarker" criteria, it represents a first step toward it.
IMPACT
Stool biomarkers can be used to predict NEC development in very low birth weight infants more than a week before the diagnosis. LCN2 was identified as a new robust biomarker for predicting NEC development, which used in conjunction with CALPRO, allows the identification of more than half of the cases that will develop NEC in very low birth weight infants. Combining more stool markers with the LCN2/CALPRO tandem such as PGE2 can further improve the algorithm for the prediction of NEC development.
Identifiants
pubmed: 34465872
doi: 10.1038/s41390-021-01680-7
pii: 10.1038/s41390-021-01680-7
pmc: PMC8770124
doi:
Substances chimiques
Biomarkers
0
LCN2 protein, human
0
Leukocyte L1 Antigen Complex
0
Lipocalin-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-136Subventions
Organisme : CIHR
ID : MOP136991
Pays : Canada
Informations de copyright
© 2021. The Author(s).
Références
Neu, J. & Walker, W. A. Necrotizing enterocolitis. N. Engl. J. Med. 364, 255–264 (2011).
pubmed: 21247316
pmcid: 3628622
doi: 10.1056/NEJMra1005408
Henry, M. C. & Moss, R. L. Necrotizing enterocolitis. Annu. Rev. Med. 60, 111–124 (2009).
pubmed: 18817461
doi: 10.1146/annurev.med.60.050207.092824
Heida, F. H. et al. Increased incidence of necrotizing enterocolitis in the Netherlands after implementation of the new Dutch guideline for active treatment in extremely preterm infants: results from three academic referral centers. J. Pediatr. Surg. 52, 273–276 (2017).
pubmed: 27923478
doi: 10.1016/j.jpedsurg.2016.11.024
Nino, D. F., Sodhi, C. P. & Hackam, D. J. Necrotizing enterocolitis: new insights into pathogenesis and mechanisms. Nat. Rev. Gastroenterol. Hepatol. 13, 590–600 (2016).
pubmed: 27534694
pmcid: 5124124
doi: 10.1038/nrgastro.2016.119
Fitzgibbons, S. C. et al. Mortality of necrotizing enterocolitis expressed by birth weight categories. J. Pediatr. Surg. 44, 1072–1075 (2009). Discussion 1075–1076.
pubmed: 19524719
doi: 10.1016/j.jpedsurg.2009.02.013
Thyoka, M. et al. Advanced necrotizing enterocolitis. Part 1: Mortality. Eur. J. Pediatr. Surg. 22, 8–12 (2012).
pubmed: 22434227
doi: 10.1055/s-0032-1306263
Jones, I. H. & Hall, N. J. Contemporary outcomes for infants with necrotizing enterocolitis—a systematic review. J. Pediatr. 220, 86–92 e83 (2020).
pubmed: 31982088
doi: 10.1016/j.jpeds.2019.11.011
Bazacliu, C. & Neu, J. Necrotizing enterocolitis: long term complications. Curr. Pediatr. Rev. 15, 115–124 (2019).
pubmed: 30864508
doi: 10.2174/1573396315666190312093119
Huda, S., Chaudhery, S., Ibrahim, H. & Pramanik, A. Neonatal necrotizing enterocolitis: clinical challenges, pathophysiology and management. Pathophysiology 21, 3–12 (2014).
pubmed: 24525171
doi: 10.1016/j.pathophys.2013.11.009
Pike, K. et al. Outcomes at 7 years for babies who developed neonatal necrotising enterocolitis: The Oracle Children Study. Arch. Dis. Child Fetal Neonatal Ed. 97, F318–322 (2012).
pubmed: 22933088
doi: 10.1136/fetalneonatal-2011-300244
Alganabi, M., Lee, C., Bindi, E., Li, B. & Pierro, A. Recent advances in understanding necrotizing enterocolitis. F1000Research 8, 107 (2019).
Eaton, S., Rees, C. M. & Hall, N. J. Current research on the epidemiology, pathogenesis, and management of necrotizing enterocolitis. Neonatology 111, 423–430 (2017).
pubmed: 28538238
doi: 10.1159/000458462
Bazacliu, C. & Neu, J. Pathophysiology of necrotizing enterocolitis: an update. Curr. Pediatr. Rev. 15, 68–87 (2019).
pubmed: 30387398
doi: 10.2174/1573396314666181102123030
Samuels, N., van de Graaf, R. A., de Jonge, R. C. J., Reiss, I. K. M. & Vermeulen, M. J. Risk factors for necrotizing enterocolitis in neonates: a systematic review of prognostic studies. BMC Pediatr. 17, 105 (2017).
pubmed: 28410573
pmcid: 5391569
doi: 10.1186/s12887-017-0847-3
Berkhout, D. J. C. et al. Risk factors for necrotizing enterocolitis: a prospective multicenter case-control study. Neonatology 114, 277–284 (2018).
pubmed: 29996136
doi: 10.1159/000489677
Cho, S. X., Berger, P. J., Nold-Petry, C. A. & Nold, M. F. The immunological landscape in necrotising enterocolitis. Expert Rev. Mol. Med. 18, e12 (2016).
pubmed: 27341512
pmcid: 5001507
doi: 10.1017/erm.2016.13
Bell, M. J. et al. Neonatal necrotizing enterocolitis. therapeutic decisions based upon clinical staging. Ann. Surg. 187, 1–7 (1978).
pubmed: 413500
pmcid: 1396409
doi: 10.1097/00000658-197801000-00001
Gilfillan, M. & Bhandari, V. Biomarkers for the diagnosis of neonatal sepsis and necrotizing enterocolitis: clinical practice guidelines. Early Hum. Dev. 105, 25–33 (2017).
pubmed: 28131458
doi: 10.1016/j.earlhumdev.2016.12.002
Gephart, S. M. et al. Changing the paradigm of defining, detecting, and diagnosing NEC: perspectives on Bell’s stages and biomarkers for NEC. Semin. Pediatr. Surg. 27, 3–10 (2018).
pubmed: 29275814
doi: 10.1053/j.sempedsurg.2017.11.002
Wang, K., Tao, G. & Sylvester, K. G. Recent advances in prevention and therapies for clinical or experimental necrotizing enterocolitis. Dig. Dis. Sci. 64, 3078–3085 (2019).
pubmed: 30989465
doi: 10.1007/s10620-019-05618-2
Ng, P. C., Ma, T. P. & Lam, H. S. The use of laboratory biomarkers for surveillance, diagnosis and prediction of clinical outcomes in neonatal sepsis and necrotising enterocolitis. Arch. Dis. Child Fetal Neonatal Ed. 100, F448–452 (2015).
pubmed: 25555389
doi: 10.1136/archdischild-2014-307656
Garg, B. D., Sharma, D. & Bansal, A. Biomarkers of necrotizing enterocolitis: a review of literature. J. Matern. Fetal Neonatal Med. 31, 3051–3064 (2018).
pubmed: 28756708
doi: 10.1080/14767058.2017.1361925
Gephart, S. M. & Newnam, K. M. Closing the gap between recommended and actual human milk use for fragile infants: what will it take to overcome disparities? Clin. Perinatol. 46, 39–50 (2019).
pubmed: 30771818
doi: 10.1016/j.clp.2018.09.003
Pergialiotis, V. et al. Calprotectin levels in necrotizing enterocolitis: a systematic review of the literature. Inflamm. Res. 65, 847–852 (2016).
pubmed: 27328832
doi: 10.1007/s00011-016-0963-9
Gollin, G. et al. Early detection of impending necrotizing enterocolitis with urinary intestinal fatty acid-binding protein. Neonatology 106, 195–200 (2014).
pubmed: 25012466
doi: 10.1159/000362497
Coufal, S. et al. Urinary I-Fabp, L-Fabp, Tff-3, and Saa can diagnose and predict the disease course in necrotizing enterocolitis at the early stage of disease. J. Immunol. Res. 2020, 3074313 (2020).
pubmed: 32190704
pmcid: 7072107
doi: 10.1155/2020/3074313
Strauss, R. G. Neonatal anemia: pathophysiology and treatment. Immunol. Invest. 24, 341–351 (1995).
pubmed: 7713595
doi: 10.3109/08820139509062784
Fallah, S. & Beaulieu, J. F. The Hippo pathway effector YAP1 regulates intestinal epithelial cell differentiation. Cells 9, 1895 (2020).
Wang, K., Tao, G., Sun, Z. & Sylvester, K. G. Recent potential noninvasive biomarkers in necrotizing enterocolitis. Gastroenterol. Res. Pract. 2019, 8413698 (2019).
pubmed: 31178908
pmcid: 6501130
doi: 10.1155/2019/8413698
Floris, I., Kraft, J. D. & Altosaar, I. Roles of microrna across prenatal and postnatal periods. Int. J. Mol. Sci. 17, 1994 (2016).
Clark, J. A. et al. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of egf treatment. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G938–949 (2006).
pubmed: 16798726
doi: 10.1152/ajpgi.00090.2006
Dvorak, B. Milk epidermal growth factor and gut protection. J. Pediatr. 156, S31–35 (2010).
pubmed: 20105663
pmcid: 2852639
doi: 10.1016/j.jpeds.2009.11.018
Nair, R. R., Warner, B. B. & Warner, B. W. Role of epidermal growth factor and other growth factors in the prevention of necrotizing enterocolitis. Semin. Perinatol. 32, 107–113 (2008).
pubmed: 18346534
doi: 10.1053/j.semperi.2008.01.007
Menard, D. et al. Anti-inflammatory effects of epidermal growth factor on the immature human intestine. Physiol. Genomics 44, 268–280 (2012).
pubmed: 22214601
doi: 10.1152/physiolgenomics.00101.2011
Ferretti, E. et al. The nitric oxide synthase 2 pathway is targeted by both pro- and anti-inflammatory treatments in the immature human intestine. Nitric Oxide 66, 53–61 (2017).
pubmed: 28315470
doi: 10.1016/j.niox.2017.03.003
Menard, D., Arsenault, P. & Pothier, P. Biologic effects of epidermal growth factor in human fetal jejunum. Gastroenterology 94, 656–663 (1988).
pubmed: 3257452
doi: 10.1016/0016-5085(88)90236-3
Nakayuenyongsuk, W. et al. Point-of-care fecal calprotectin monitoring in preterm infants at risk for necrotizing enterocolitis. J. Pediatr. 196, 98–103 e101 (2018).
pubmed: 29519542
doi: 10.1016/j.jpeds.2017.12.069
MacQueen, B. C. et al. Reference intervals for stool calprotectin in preterm neonates and their utility for the diagnosis of necrotizing enterocolitis. J. Perinatol. 38, 1379–1385 (2018).
pubmed: 29740189
doi: 10.1038/s41372-018-0108-9
Zoppelli, L. et al. Fecal Calprotectin concentrations in premature infants have a lower limit and show postnatal and gestational age dependence. Neonatology 102, 68–74 (2012).
pubmed: 22613938
doi: 10.1159/000337841
van Zoonen, A. et al. Serial fecal calprotectin in the prediction of necrotizing enterocolitis in preterm neonates. J. Pediatr. Surg. 54, 455–459 (2019).
pubmed: 29859621
doi: 10.1016/j.jpedsurg.2018.04.034
Nielsen, B. S. et al. Induction of Ngal synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 38, 414–420 (1996).
pubmed: 8675096
pmcid: 1383072
doi: 10.1136/gut.38.3.414
Chassaing, B. et al. Fecal Lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS ONE 7, e44328 (2012).
pubmed: 22957064
pmcid: 3434182
doi: 10.1371/journal.pone.0044328
Oikonomou, K. A. et al. Neutrophil gelatinase-associated Lipocalin (Ngal) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J. Gastroenterol. 47, 519–530 (2012).
pubmed: 22200942
doi: 10.1007/s00535-011-0516-5
Tremblay, E. et al. Gene expression profiling in necrotizing enterocolitis reveals pathways common to those reported in Crohn’s disease. BMC Med. Genomics 9, 6 (2016).
pubmed: 26801768
pmcid: 4722613
doi: 10.1186/s12920-016-0166-9
Hendel, J. & Nielsen, O. H. Expression of Cyclooxygenase-2 Mrna in active inflammatory bowel disease. Am. J. Gastroenterol. 92, 1170–1173 (1997).
pubmed: 9219792
Singer, I. I. et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115, 297–306 (1998).
pubmed: 9679035
doi: 10.1016/S0016-5085(98)70196-9
Jiang, G. L. et al. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J. Pharmacol. Exp. Ther. 320, 22–28 (2007).
pubmed: 17008451
doi: 10.1124/jpet.106.111146
Miyoshi, H. et al. Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. EMBO J. 36, 5–24 (2017).
pubmed: 27797821
doi: 10.15252/embj.201694660
Kandil, H. M., Argenzio, R. A. & Sartor, R. B. Low endogenous prostaglandin E2 predisposes to relapsing inflammation in experimental rat enterocolitis. Dig. Dis. Sci. 45, 2091–2099 (2000).
pubmed: 11215721
doi: 10.1023/A:1026675005554
Salzman, N. H. et al. enteric defensin expression in necrotizing enterocolitis. Pediatr. Res. 44, 20–26 (1998).
pubmed: 9667365
doi: 10.1203/00006450-199807000-00003
Puiman, P. J. et al. Paneth cell hyperplasia and metaplasia in necrotizing enterocolitis. Pediatr. Res. 69, 217–223 (2011).
pubmed: 21372757
doi: 10.1203/PDR.0b013e3182092a9a
Shiotani, A. et al. Application of fecal hemoglobin-haptoglobin complex testing for small bowel lesions. Scand. J. Gastroenterol. 49, 539–544 (2014).
pubmed: 24621414
doi: 10.3109/00365521.2014.891260
MohanKumar, K. et al. A murine neonatal model of necrotizing enterocolitis caused by anemia and red blood cell transfusions. Nat. Commun. 10, 3494 (2019).
pubmed: 31375667
pmcid: 6677753
doi: 10.1038/s41467-019-11199-5
Nahidi, L. et al. Osteoprotegerin in pediatric Crohn’s disease and the effects of exclusive enteral nutrition. Inflamm. Bowel Dis. 17, 516–523 (2011).
pubmed: 20848544
doi: 10.1002/ibd.21361
Sylvester, F. A. et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm. Bowel Dis. 17, 1726–1730 (2011).
pubmed: 21744427
doi: 10.1002/ibd.21561
Heath, M. et al. Association of intestinal alkaline phosphatase with necrotizing enterocolitis among premature infants. JAMA Netw. Open 2, e1914996 (2019).
pubmed: 31702803
pmcid: 6902776
doi: 10.1001/jamanetworkopen.2019.14996
Abella, V. et al. The potential of Lipocalin-2/Ngal as biomarker for inflammatory and metabolic diseases. Biomarkers 20, 565–571 (2015).
pubmed: 26671823
pmcid: 4819811
doi: 10.3109/1354750X.2015.1123354